 |
|---|
About trainings
The objective of MPP is to support synergies between the pharma, medtech, and tech industries by establishing a forum to exchange knowledge and collaborate in the areas of technology and regulatory policy, while building stakeholder consensus to promote product development and innovation.
To this aim, MPP dispenses accredited trainings throughout the year in addition to its annual meeting.
Target audience: Professionals and individuals in the pharma, medtech and tech sectors.
Topics: The topics are varied, but broadly cover industry, regulatory and technical developments.
Course leaders: All trainings are given by topic experts.
SwAPP accreditation: Training courses organized by MPP are accredited by the Swiss Association of Pharmaceutical Professionals (SwAPP). Participants in the training courses can receive SwAPP credits.
Upcoming training
24 June 2021, 2:00-5:00 pm CEST
Development and regulatory considerations for connected combined products
Shayesteh Fürst-Ladani, MPP
SFL CEO and MPP President
Oliver Shergold, Novartis
Head of Ecosystem Operations
Tomaso Scherini, Philips Engineering Solutions
Business Partner
Abtin Rad, TÜV SÜD
Global Director Functional Safety
Christiana Hofmann, TÜV SÜD
Regional Manager Focus Topics Article 117 & Annex XVI MDR
Past training courses & webinars
26 May 2021, 1:00-3:45 pm CEST
Introduction to clinical evaluation under the MDR
Shayesteh Fürst-Ladani
SFL CEO and MPP President
Marta Swierczynska, SFL
Senior Manager Regulatory Affairs
Patricia McHugh Giordano, MSD
Executive Director, Medical Safety Lead for Devices and Product Quality
Joshua Samuels, Johnson & Johnson
Director of Clinical Evaluations
Alice Genevet, SFL
Senior Manager Medical Affairs & Regulatory Affairs
Ulrich Nitsche, TÜV-SÜD
Clinical Reviewer
27 April 2021, 3:00-4:00 pm CEST /
2:00-3:00 pm GMT
Joint webinar MPP / UK Department for International Trade in Switzerland
Shayesteh Fürst-Ladani
SFL CEO and MPP President
Helen Stubbs, UK Department for International Trade in Switzerland
Senior Inward Investment Officer
Neil Ebenezer, UK Department for International Trade
Medtech Senior Specialist Advisor
Alex Mclaughlin, UK Office for Life Sciences (OLS)
Head of International Trade and Medical Device Regulation
16 February 2021
Virtual Training Course
Introduction to the EU MDR art. 117 and single integral drug/device combination products
Shayesteh Fürst-Ladani
SFL CEO and MPP President
_AffolterS_JPG.jpg)
Stephan Affolter, Ypsomed
Regulatory and Quality Intelligence Manager
Christiana Hofmann, TÜV-SÜD
Teamlead Non Active Medical Devices / Article 117 MDR
Mike Wallenstein, Novartis
Global Head MDR Implementation & DD&C Compliance